ProQR TherapeuticsPRQR
PRQR
About: ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
Employees: 157
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
375% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 8
271% more capital invested
Capital invested by funds: $31.7M [Q3] → $118M (+$86M) [Q4]
183% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 6
82% more call options, than puts
Call options by funds: $296K | Put options by funds: $163K
62% more funds holding
Funds holding: 47 [Q3] → 76 (+29) [Q4]
33.61% more ownership
Funds ownership: 21.36% [Q3] → 54.96% (+33.61%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
141%
upside
Avg. target
$8
382%
upside
High target
$12
623%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Evercore ISI Group Gavin Clark-Gartner 42% 1-year accuracy 5 / 12 met price target | 201%upside $5 | Outperform Initiated | 29 Apr 2025 |
Chardan Capital Keay Nakae 18% 1-year accuracy 13 / 73 met price target | 141%upside $4 | Buy Maintained | 14 Mar 2025 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 354 met price target | 623%upside $12 | Buy Maintained | 14 Mar 2025 |
Jones Trading Catherine Novack 22% 1-year accuracy 2 / 9 met price target | 563%upside $11 | Buy Initiated | 12 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV.
Negative
Zacks Investment Research
1 month ago
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.08 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
ProQR Announces Year End 2024 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2024, and provided a business update.
Neutral
GlobeNewsWire
4 months ago
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term collaborator of ProQR and a valued member of ProQR's Scientific Advisory Board, where he has played an important role in shaping the Company's ADAR-based RNA editing platform.
Neutral
GlobeNewsWire
6 months ago
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the closing of its previously announced underwritten public offering of 18,000,000 ordinary shares (the “Offering”) at a public offering price of $3.50 per share, for total gross proceeds of $63.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. All of the shares in the Offering were sold by ProQR.
Neutral
GlobeNewsWire
6 months ago
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of its previously announced underwritten public offering of 18,000,000 ordinary shares (the “Offering”) at a public offering price of $3.50 per share, for total gross proceeds of $63.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. All of the shares are being offered by ProQR. In addition, ProQR has granted the underwriters a 30-day option to purchase up to 2,700,000 additional ordinary shares at the public offering price, less underwriting discounts and commissions.
Neutral
GlobeNewsWire
6 months ago
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it has commenced an underwritten public offering of its ordinary shares (the “Offering”). All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the offering amount in ordinary shares at the public offering price, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual terms of the Offering.
Neutral
GlobeNewsWire
6 months ago
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present preclinical data for its proprietary Axiomer™ RNA editing technology platform and its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society, October 6-9, 2024, in Montreal, QC, Canada.
Positive
Zacks Investment Research
6 months ago
Best Momentum Stocks to Buy for October 2nd
BRFS, SNAX, and PCQR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 2, 2024.
Neutral
GlobeNewsWire
7 months ago
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform today announced that Company management is scheduled to present at the 2024 Cantor Global Healthcare Conference in New York City on Tuesday, September 17 at 9:10 am ET.
Charts implemented using Lightweight Charts™